RecruitingPhase 1NCT05227326

AOH1996 for the Treatment of Refractory Solid Tumors

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors

Sponsor

City of Hope Medical Center

Enrollment

92 participants

Start Date

Aug 12, 2022

Study Type

INTERVENTIONAL

Conditions

Ovarian Cancer Refractory Malignant Solid Neoplasm Osteosarcoma Leiomyosarcomas Synovial Sarcomas

Summary

This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This early-phase trial is testing a new experimental drug called AOH1996, which targets a protein involved in DNA replication in cancer cells, in patients with advanced solid tumors that have stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older - You have a confirmed solid tumor that has not responded to standard therapies - You are in reasonably good general health (ECOG performance status 0–2) - You have a life expectancy of more than 3 months - You are willing to provide a tissue sample if one is already available **You may NOT be eligible if...** - You have received cancer treatment recently without enough washout time - You have uncontrolled brain metastases - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding - You have active infections or autoimmune conditions requiring treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.